AZD9833 with palbociclib

Phase 1

AZD9833 with palbociclib is one of 6 therapeutic programs targeting ER+ HER2- Advanced Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

ER+ HER2- Advanced Breast CancerActive, not recruiting

ER+ HER2- Advanced Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in ER+ HER2- Advanced Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Verzenio

Eli Lilly

Preclinical

1 4

AZD9833

AstraZeneca

Phase 1

1 5

Camizestrant

AstraZeneca

Preclinical

1 6

AZD9833 with palbociclib

AstraZeneca

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

ER+ HER2- Advanced Breast Cancer

NCT03616587

Clinical

Trials by Indication[1]

ER+ HER2- Advanced Breast Cancer1 trial

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT03616587·396 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD9833 with palbociclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AZD9833 with palbociclib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AstraZeneca

AZD9833 with palbociclib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

ER+ HER2- Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News